Straits Times Index
3,342.99 -0.36 (-0.01%) Nikkei
39,713.40 +371.86 (+0.95%) Hang Seng
17,831.12 +114.65 (+0.65%) FTSE 100
8,179.68 -45.65 (-0.55%) Bitcoin USD
61,865.39 +967.34 (+1.59%) CMC Crypto 200
1,290.53 +24.38 (+1.93%)
SCLX Jul 2024 2.000 call
| Previous close | 0.1000 |
| Open | 0.1000 |
| Bid | 0.2000 |
| Ask | 0.2500 |
| Strike | 2.00 |
| Expiry date | 2024-07-19 |
| Day's range | 0.1000 - 0.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.6k |
GlobeNewswireScilex Holding Company Partners with New National Distributor, Endeavor Distribution LLC.
PALO ALTO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that in anticipation of selling our commercially available products to new and current special customers, Scilex has entered into a non-exclusive distribution agreement with a well-known and
- GlobeNewswire
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the International Association for the Study of Pain, and features original research on the nature, mechanisms and treatment of pain.This Phase 3 study met primary and important key secondary endpoints, with SP-102 (SEMDEXA™) treatment, decreasing pain intensity for over a month in sciatica patients and resulting in statistically signi
Simply Wall St.Scilex Holding Company (NASDAQ:SCLX) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on Scilex Holding Company ( NASDAQ:SCLX ) - they aren't optimistic, having...
